Short answer
Viatris (VTRS) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Viatris completed Pacira acquisition on November 17, 2026, making Pacira a wholly owned subsidiary.
Viatris 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Viatris completed Pacira acquisition on November 17, 2026, making Pacira a wholly owned subsidiary
- Offer price $36.50 per share in cash, with 32,929,780 shares tendered, representing 66.46% ownership
- Aggregate purchase consideration approximately $1.69 billion, excluding fees and expenses
- Funding mix: Viatris cash on hand and short-term borrowings, creating near-term financing needs
- Transaction closed without a Pacira stockholder vote under Delaware Section 251(h)
Item 7.01 · Regulation FD Disclosure
- Viatris announced consummation of the Merger, marking completion of a material corporate transaction
- Investors should review Exhibit 99.1 for merger consideration, strategic rationale and expected financial impact
Item EX-99.1 · Exhibit EX-99.1
- Viatris completed Pacira acquisition, adding Pacira’s non-opioid pain portfolio to its U.S. innovative medicines business
- Cash consideration of $36.50 per share, with approximately 32,929,780 shares tendered, representing 66.46% of outstanding shares
- Pacira became a wholly owned Viatris subsidiary through a merger without a stockholder vote
- Expected revenue contribution of $90 million to $100 million for Nov. 17 through Dec. 31, 2026
- Pacira shares will be delisted from the Nasdaq Global Select Market
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viatris 8-K filings
Get the next VTRS 8-K as it lands
Follow VTRS for push alerts, or ask the research agent what this filing means.